> Aggressively looking to expand its role in biologics, Pfizer has struck a deal to buy CovX. No figures were given. Report
> Florida's governor has committed $94 million to bring the Max Planck Society to Palm Beach County, making it a neighbor of Scripps Florida. Report
> Affymetrix is buying USB, which makes molecular biology and biochemical reagent products, for $75 million. Release
> The FDA has approved Forest Laboratories' hypertension drug Bystolic, which it plans to launch next month. Release
> Human Genome Sciences says that animal studies of a new anthrax therapy have demonstrated marked results. Release
> Insmed has received the FDA's Orphan Drug Designation for IPLEX, a treatment of myotonic muscular dystrophy. Release
> Elixir set the terms for its IPO at $14 to $16 a share. Report
> Belgium's Ablynx is touting the results of a Phase I trial of its ALX-0081 nanobody for thrombosis. Release
> Biomarin announced today that it has re-acquired the Canadian rights for tetrahydrobiopterin, including Kuvan, from Merck Serono, The FDA has granted marketing approval for BioMarin Pharmaceutical's Kuvan tablets, a specific drug therapy for the treatment of phenylketonuria. Release
> Medarex will receive an undisclosed milestone payment from Amgen for advancing an antibody into human clinical trials. Release
> Merck and Schering-Plough have responded to public outcry over their plans to re-jig a study of Vytorin, a joint product that combines Merck's Zocor and Schering-Plough's Zetia. Report
> The Internet is buzzing about a Wall Street Journal op-ed piece in which ex-FDA deputy commissioner Scott Gottlieb (photo) championed the sort of off-label promotions that make regulators crazy. Report
> Counterfeit drugmakers have found some unlikely allies: free trade zones. Report
And Finally… A new DNA sequencing technique could dramatically lower the cost to read human genomes. Article